ECSP961779A - PROCEDURES TO MINIMIZE LOSS OSEA X-10221 - Google Patents
PROCEDURES TO MINIMIZE LOSS OSEA X-10221Info
- Publication number
- ECSP961779A ECSP961779A ECSP961779A ECSP961779A EC SP961779 A ECSP961779 A EC SP961779A EC SP961779 A ECSP961779 A EC SP961779A EC SP961779 A ECSP961779 A EC SP961779A
- Authority
- EC
- Ecuador
- Prior art keywords
- compound
- formula
- pyrrolidinyl
- alkyl
- osea
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 3
- 206010065687 Bone loss Diseases 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- -1 methyl-1-pyrrolidinyl Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 229940124325 anabolic agent Drugs 0.000 abstract 1
- 239000003263 anabolic agent Substances 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
El invento se refiere a un procedimiento para minimizar el efecto de la pérdida ósea de un compuesto de fórmula II (gráfico) o una de sus sales farmacéuticamente aceptable, en la que dicho compuesto de fórmula II se administra a un mamífero en necesidad de tratamiento, que comprende administrar de forma concurrente o secuenciual a dicho mamífero una cantidad eficaz de un compuesto de fórmula I. (gráfico), en la que cada R1 es independientemente -H, -OH, -(alquilo de C1-C4), OCOC6H5, -OCO(alquilo de C1-C6) U -OSO2( alquilo de C4, C6); y R2 es 1-piperidinilo, 1-pirrolidinilo, metil-1-pirrolidinilo, dimetil-1- pirrolidinilo, 4-morfolino dimetilamino, dietilamino o 1 -hexametilenimino; o una de las sales farmacéuticamente aceptables del mismo. También se proporciona un procedimiento para minimizar la perdida ósea inducida por la administración de un compuesto de fórmula II que comprende administrar de una forma concurrente o secuencial un agente anabólico óseo. También se proporcionancomposiciones farmacéuticas.The invention relates to a method of minimizing the bone loss effect of a compound of formula II (graph) or a pharmaceutically acceptable salt thereof, wherein said compound of formula II is administered to a mammal in need of treatment, comprising administering concurrently or sequentially to said mammal an effective amount of a compound of formula I. (graph), wherein each R1 is independently -H, -OH, - (C1-C4 alkyl), OCOC6H5, - OCO (C1-C6 alkyl) U -OSO2 (C4, C6 alkyl); and R2 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino dimethylamino, diethylamino or 1-hexamethyleneimino; or one of the pharmaceutically acceptable salts thereof. A method is also provided to minimize bone loss induced by administration of a compound of formula II which comprises administering a bone anabolic agent concurrently or sequentially. Pharmaceutical compositions are also provided.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP961779 ECSP961779A (en) | 1996-06-06 | 1996-06-06 | PROCEDURES TO MINIMIZE LOSS OSEA X-10221 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP961779 ECSP961779A (en) | 1996-06-06 | 1996-06-06 | PROCEDURES TO MINIMIZE LOSS OSEA X-10221 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP961779A true ECSP961779A (en) | 1997-11-04 |
Family
ID=42042509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP961779 ECSP961779A (en) | 1996-06-06 | 1996-06-06 | PROCEDURES TO MINIMIZE LOSS OSEA X-10221 |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP961779A (en) |
-
1996
- 1996-06-06 EC ECSP961779 patent/ECSP961779A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR024060A1 (en) | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | |
| AR037517A1 (en) | DERIVATIVES OF NAFTIRIDINES, A PROCESS FOR THE PREPARATION, PHARMACEUTICAL COMPOSITION AND THE USE OF THEM FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF AN INFLAMMATORY DISEASE | |
| GT199800180A (en) | DERIVATIVES OF THENOPyrimidine AND THENOPyridine USEFUL AS ANTI-CANCER AGENTS. | |
| PA8451801A1 (en) | DERIVATIVES OF 9-OXYME ERYTHROMYCIN | |
| AR009052A1 (en) | THENOPYRIMIDINES, A PROCEDURE FOR THEIR PREPARATION, USE OF THE SAME TO PREPARE A MEDICINAL PRODUCT, PHARMACEUTICAL PREPARATIONS THAT CONSTITUTE THEM AND A PROCEDURE TO OBTAIN THESE PHARMACEUTICAL PREPARATIONS | |
| AR029634A1 (en) | USEFUL HETEROCICLIC DERIVATIVE COMPOUNDS AS ANTI-TARGET AGENTS, PHARMACEUTICAL COMPOSITION AND PROCESSING PROCEDURE | |
| ECSP034897A (en) | 4'-SUBSTITUTED NUCLEOSIDS | |
| UY26635A1 (en) | SYNERGIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
| PA8452001A1 (en) | DERIVATIVES OF MACROLIDES C-4 "SUBSTITUTED | |
| AR003930A1 (en) | PROCEDURE FOR PREPARING COMPOUNDS OF 2-PHENYL-3-PHENOXY OR PHENYLTIO-BENZOTIOFEN AND PHARMACEUTICALLY ACCEPTABLE SALTS, INTERMEDIATE COMPOUNDS OF EXCLUSIVE APPLICATION IN SUCH PROCEDURE AND METHOD FOR PREPARING INTERMEDIATE COMPOUNDS | |
| CO5570677A2 (en) | QUINOLINILPIRROLOPIRAZOLES | |
| BR0010938A (en) | 13-Methyl erythromycin derivatives | |
| AR019496A1 (en) | AZALIDAS OF 13 MEMBERS, PHARMACEUTICAL COMPOSITIONS, USE IN THE PREPARATION OF MEDICINES AND PREPARATION OF THE SAME | |
| ECSP045301A (en) | USE OF INDOLOPIRROLOCARBAZOL DERIVATIVE AND OTHER ANTI-TARGET AGENTS IN COMBINATION | |
| AR030007A1 (en) | CYCLOHEXILO COMPOUND, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, DIAGNOSTIC AGENT, PHARMACEUTICAL COMPOSITION CONTAINING IT, PROCESS FOR PREPARATION, COMPOUNDS FOR ITS EXCLUSIVE USE IN THE PREPARATION OF SUCH CYCLODOOD METHODOIL COMPOUNDS, | |
| AR032617A1 (en) | USE OF BIGUANIDA DERIVATIVES TO MANUFACTURE A MEDICINAL PRODUCT THAT HAS A CICATRIZING EFFECT | |
| TW372969B (en) | Pharmaceutical composition for minimizing bone loss | |
| ATE268174T1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING SIBUTRAMIN AND ORLISTAT | |
| PE20231945A1 (en) | REGIMES FOR THE TREATMENT OF HAIR LOSS DISORDERS WITH DEUTERATED JAK INHIBITORS | |
| ECSP066349A (en) | FARNESIL PROTEIN TRANSFER INHIBITORS NOVEDOSOS AS ANTITUMOR AGENTS | |
| ES2179523T3 (en) | METHOD TO INCREASE THE BIODISPONIBILITY OF FEXOFENADINE AND ITS DERIVATIVES. | |
| AR029302A1 (en) | 1,4-REPLACED PHENYL COMPOUND, THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, DIAGNOSTIC AGENT, PHARMACEUTICAL COMPOSITION CONTAINING IT AND PROCESS FOR PREPARATION | |
| AR029001A1 (en) | DERIVATIVES OF BENCIL-3,4-METHYLENDIOXYCHINAMIC AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT | |
| UY26459A1 (en) | 3,4-DIHIDROQUINAZOLINES 5,6-DISSTITUTED | |
| ECSP961779A (en) | PROCEDURES TO MINIMIZE LOSS OSEA X-10221 |